Sargen Michael R, Barnhill Raymond L, Elder David E, Swetter Susan M, Prieto Victor G, Ko Jennifer S, Bahrami Armita, Gerami Pedram, Karunamurthy Arivarasan, Pappo Alberto S, Schuchter Lynn M, LeBoit Philip E, Yeh Iwei, Kirkwood John M, Jen Melinda, Dunkel Ira J, Durham Megan M, Christison-Lagay Emily R, Austin Mary T, Aldrink Jennifer H, Mehrhoff Casey, Hawryluk Elena B, Chu Emily Y, Busam Klaus J, Sondak Vernon, Messina Jane, Puig Susana, Colebatch Andrew J, Coughlin Carrie C, Berrebi Kristen G, Laetsch Theodore W, Mitchell Sarah G, Seynnaeve Brittani
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD.
Department of Translational Research, Institut Curie, Unit of Formation and Research of Medicine University of Paris Cité, Paris, France.
J Clin Oncol. 2025 Mar 20;43(9):1157-1167. doi: 10.1200/JCO.24.01154. Epub 2024 Oct 4.
The purpose of this study was to develop recommendations for the diagnostic evaluation and surgical management of cutaneous melanoma (CM) and atypical Spitz tumors (AST) and non-Spitz melanocytic tumors (melanocytomas) in pediatric (age 0-10 years) and adolescent (age 11-18 years) patients.
A Children's Oncology Group-led panel with external, multidisciplinary CM specialists convened to develop recommendations on the basis of available data and expertise.
Thirty-three experts from multiple specialties (cutaneous/medical/surgical oncology, dermatology, and dermatopathology) established recommendations with supporting data from 87 peer-reviewed publications.
(1) Excisional biopsies with 1-3 mm margins should be performed when feasible for clinically suspicious melanocytic neoplasms. (2) Definitive surgical treatment for CM, including wide local excision and sentinel lymph node biopsy (SLNB), should follow National Comprehensive Cancer Network Guidelines in the absence of data from pediatric-specific surgery trials and/or cohort studies. (3) Accurate classification of ASTs as benign or malignant is more likely with immunohistochemistry and next-generation sequencing. (4) It may not be possible to classify some ASTs as likely/definitively benign or malignant after clinicopathologic and/or molecular correlation, and these Spitz tumors of uncertain malignant potential should be excised with 5 mm margins. (5) ASTs favored to be benign should be excised with 1- to 3-mm margins if transected on biopsy. (6) Re-excision is not necessary if the AST does not extend to the biopsy margin(s) when complete/excisional biopsy was performed. (7) SLNB should not be performed for Spitz tumors unless a diagnosis of CM is favored on clinicopathologic evaluation. (8) Non-Spitz melanocytomas have a presumed increased risk for progression to CM and should be excised with 1- to 3-mm margins if transected on biopsy. (9) Re-excision of non-Spitz melanocytomas is not necessary if the lesion is completely excised on biopsy.
本研究的目的是针对儿童(0至10岁)和青少年(11至18岁)患者的皮肤黑色素瘤(CM)、非典型斯皮茨肿瘤(AST)和非斯皮茨黑素细胞肿瘤(黑素细胞瘤)的诊断评估及手术管理制定建议。
由儿童肿瘤学组牵头,联合外部多学科CM专家组成小组,根据现有数据和专业知识制定建议。
来自多个专业领域(皮肤/医学/外科肿瘤学、皮肤科和皮肤病理学)的33位专家依据87篇同行评审出版物中的支持数据制定了建议。
(1)对于临床可疑的黑素细胞肿瘤,可行时应进行切缘为1至3毫米的切除活检。(2)在缺乏儿科特定手术试验和/或队列研究数据的情况下,CM的确定性手术治疗,包括广泛局部切除和前哨淋巴结活检(SLNB),应遵循美国国立综合癌症网络指南。(3)免疫组织化学和下一代测序更有可能准确将AST分类为良性或恶性。(4)经临床病理和/或分子关联后,可能无法将某些AST分类为可能/明确良性或恶性,这些恶性潜能不确定的斯皮茨肿瘤应切缘5毫米切除。(5)活检时横切的、倾向于为良性的AST,应切缘1至3毫米切除。(6)若进行完整/切除活检时AST未累及活检切缘,则无需再次切除。(7)除非临床病理评估倾向于诊断为CM,否则斯皮茨肿瘤不应进行SLNB。(8)非斯皮茨黑素细胞瘤进展为CM的风险假定增加,活检时横切的应切缘1至3毫米切除。(9)若活检时病变完整切除,则无需再次切除非斯皮茨黑素细胞瘤。